Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2187784 | 0.83 | LMNA (0.69) | LMNASMN1; SMN2RAB9ANPC1MEN1 | |
| SCHEMBL7143641 | 0.83 | LMNA (1.00) | LMNASMN1; SMN2RAB9ANPC1MEN1 | |
| SCHEMBL2644386 | 0.83 | SMN1; SMN2 (0.69) | LMNASMN1; SMN2RAB9ANPC1MEN1 | |
| SCHEMBL2619292 | 0.82 | SMN1; SMN2 (0.68) | LMNASMN1; SMN2RAB9ANPC1MEN1 | |
| SCHEMBL8391808 | 0.80 | LTA4H (0.69) | LMNASMN1; SMN2RAB9ANPC1MEN1 | |
| SCHEMBL7873175 | 0.80 | LTA4H (0.64) | LMNASMN1; SMN2RAB9ANPC1MEN1 | |
| SCHEMBL18590264 | 0.80 | SMN1; SMN2 (0.65) | LMNASMN1; SMN2RAB9ANPC1HTT | |
| SCHEMBL3541038 | 0.80 | LMNA (0.65) | LMNASMN1; SMN2RAB9ANPC1HTT | |
| SCHEMBL13064251 | 0.80 | LMNA (0.65) | LMNASMN1; SMN2RAB9ANPC1KMT2A | |
| SCHEMBL5507744 | 0.79 | LMNA (0.64) | LMNASMN1; SMN2RAB9AKMT2AAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3138840-B1 | THIADIAZOLIDINE DERIVATIVE AS ANTI-ENTEROVIRUS 71 | JIANGSU KANION PHARMACEUTICAL CO LTD (CN) | 2020-09-23 | — | — | EP | disclosed |
| EP-3255044-B1 | DIAZA-BENZOFLUORANTHRENE COMPOUNDS | HARBIN PHARMACEUTICAL GROUP CO LTD GENERAL PHARMACEUTICAL FACTORY (CN) | 2020-04-01 | — | — | EP | disclosed |
| US-20170240519-A1 | BENZOFURAN ANALOGUE AS NS4B INHIBITOR | CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) | 2017-08-24 | — | — | US | disclosed |
| EP-3199530-A1 | BENZOFURAN ANALOGUE AS NS4B INHIBITOR | Changzhou Yinsheng Pharmaceutical Co., Ltd. (CN) | 2017-08-02 | — | — | EP | disclosed |
| US-7683070-B2 | N-(substituted arylmethyl)-4-(disubstituted methyl) piperidines and pyridines | FMC CORPORATION (US) | 2010-03-23 | — | — | US | disclosed |
| US-7365082-B2 | N-(substituted arylmethyl)-4-(disubstituted methyl)piperidines and piperazines | BAYER CROPSCIENCE AG (DE) | 2008-04-29 | — | — | US | disclosed |
| US-20080090828-A1 | N-(substituted arylmethyl)-4-(disubstituted methyl) piperidines and pyridines | BAYER CROPSCIENCE AG (DE) | 2008-04-17 | — | — | US | disclosed |
| US-7300946-B2 | N-(substituted arylmethyl)-4-(disubstituted methyl) piperidines and pyridines | BAYER CROPSCIENCE AG (DE) | 2007-11-27 | — | — | US | disclosed |
| EP-1572668-A4 | N-(SUBSTITUTED ARYLMETHYL)-4-(DISUBSTITUTED METHYL)PIPERIDINES AND PIPERAZINES | FMC CORP (US) | 2006-12-06 | — | — | EP | disclosed |
| EP-1572207-A4 | N-(SUBSTITUTED ARYLMETHYL)-4-(DISUBSTITUTED METHYL) PIPERIDINES AND PYRIDINES | FMC CORP (US) | 2006-11-29 | — | — | EP | disclosed |
| US-20060166962-A1 | N-(substituted arylmethyl)-4-(disubstituted methyl)piperidines and piperazines | FMC CORPORATION | 2006-07-27 | — | — | US | disclosed |
| US-20060135504-A1 | N-(substituted arylmethyl)-4-(disubstituted methyl) piperidines and pyridines | FMC CORPORATION | 2006-06-22 | — | — | US | disclosed |
| EP-1572207-A1 | N-(SUBSTITUTED ARYLMETHYL)-4-(DISUBSTITUTED METHYL) PIPERIDINES AND PYRIDINES | FMC CORPORATION (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1572668-A2 | N-(SUBSTITUTED ARYLMETHYL)-4-(DISUBSTITUTED METHYL)PIPERIDINES AND PIPERAZINES | FMC CORPORATION (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004060865-A2 | N-(SUBSTITUTED ARYLMETHYL)-4-(DISUBSTITUTED METHYL)PIPERIDINES AND PIPERAZINES | FMC CORPORATION (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004060371-A1 | N-(SUBSTITUTED ARYLMETHYL)-4-(DISUBSTITUTED METHYL) PIPERIDINES AND PYRIDINES | FMC CORPORATION (US) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166962-A1 | N-(substituted arylmethyl)-4-(disubstituted methyl)piperidines and piperazines | DDT, DRD4, DRD1 | LMNA 1988/4885SMN1; SMN2 1048/4885RAB9A 127/4885 |
| US-20060135504-A1 | N-(substituted arylmethyl)-4-(disubstituted methyl) piperidines and pyridines | DDT, DRD4, QDPR | LMNA 2216/4885SMN1; SMN2 1254/4885RAB9A 61/4885 |
| US-20080090828-A1 | N-(substituted arylmethyl)-4-(disubstituted methyl) piperidines and pyridines | DDT, DRD4, QDPR | LMNA 2194/4885SMN1; SMN2 1192/4885RAB9A 56/4885 |
| US-20170240519-A1 | BENZOFURAN ANALOGUE AS NS4B INHIBITOR | GTF3C4, BRD4, CUL4B | LMNA 3517/4885SMN1; SMN2 2019/4885RAB9A 2917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.